Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Did something similar a few years ago. Slipped up on some wet patio on the way to my koi pond and broke my ankle - It sounds like a log snapping when it went!
Also ended up next to a dementia sufferer in hospital, who couldn't stop shouting. Was a difficult few days in hospital.
Hope the Doctors get this sorted for you soon - please keep us all updated.
Best,
Bill
"Falling heavily in supermarket", while making a bee-line for the booze section? Respect! Wishing you a speedy recovery, sir.
There are still funds outstanding due to RF. All this is saying is that Sareum won't be going to RF for any additional funds.
B.
Sorry to hear that Warthog wishing you a speedy return home .. did you say Robin Hood and Puma were in with you 😵💫😵💫
Company does not intend to make any further withdrawals pursuant to the Equity Prepayment Facility with RiverFort.
Ouch, get well soon !
.... By falling heavily in supermarket, cracking hip and fracturing femur. Now stuck in hospital in a ward with a dementia sufferer who rambles on day and night
O Joy!
Https://www.fiercebiotech.com/biotech/gilead-pays-435m-xilios-early-phase-il-12-prospect-entering-race-after-rivals-exit
This is what we're waiting for, all genuine investors and LTH are waiting for a license, obviously we could sell, and probably have sold on previous highs making a substantial amount of money. To say it's not investible is very short sighted.
Nobody cares about what happened with finances when they sign a license, they need the compound to be viable to do that and to date nothing suggests it's not a blockbuster.
Take a look at Jeb Keipers comments before Nimbus signed a $4 billion deal for their TYK2 compound.
We've moved to a P2a strategy, possibly OZ driven as original admission was with MHRA. Those who talked about doing the trial in UK - no chance. MHRA are the ones that set us on this path of financial woe in the first place.
28 SOG
Be 27 or even 26 if LLoyds were participating
Crazy they are not
This is pretty much the same as Synairgen and numerous other AIM bio Pharma’
They can’t get the product through trials and they don’t know how to commercialise it
Neither company is investible
Are you speaking of efficacy? If 1801 has superior efficacy then the value is huge...
However 1801 hasn't finished phase 1a safety trials yet. And Sareum may not have the funding to put 1801 through a phase 1b / 2a efficacy trial.
This is the issue. Sareum might not have funding to find out if it has a superior product.
It really doesn't matter if it is 'potentially' better - if it doesn't have the money to demonstrate this.
This is why the share price is where it is. This is also why investors are sick of hearing how good it 'might' be, at some point in the future 'if' there's any funding left.
Should the retail offer have been for £1m?
Placing yesterday at 10p
Some fall from the Hardman & Co printed "On the evidence of GDR, guess where the share price is going! " when they were 30p 11th March less then three weeks ago.
I see Alans55 you are the most recommended poster on the site how many times have you averaged down.
Jeez cobalt all it requires is 29 other people like myself who have applied for shares
Give Sareum their due they have made this option open to current shareholders.
What value would you place should 1801 prove superior to Deucravacitinib?
It will be better in Psoriasis, of that l have the upmost confidence
If the retail offer is oversubscribed ( which I think it will be) that would indicate that many people believe that 10p is the floor. Personally, I think 10p will more or less hold. This could be the nadir moment.
No they don’t do retail offers at Lloyd’s grrrrrr!
Nope.. but try online and not on the phone. I just bought them normally, not on the offer
Is that where we are headed again?
Guys - anyone had notification of the retail offer from LLoyds ?
I am
If you think the earliest HNWI, who got in at 1p ish was still in at 10p then you're mad. i suspect that all the HNWI buys were worked by the same one or two who circulated their buys into the rising sp and i doubt any of them were still in for more than a few weeks, if that.
as to the current sp, it was walked down to the placing price. it didn't fall coincidentally!
the only problem for the share now is it'll take a bloody good piece of news to push the price past 10%ers now beyond better than 14p if that!
but, given time, don't see why 40-50p isn't unreasonable.
I must admit I am a little surprised by the RNS.
With the Dec 21 HNWIs losing 95% of their investment, if they have stayed the course, I wasn't expecting them or similar to stump up more cash.
I would also have expected the offer to be at a greater discount to the current share price, it's not attracting me. I might wait and see if this downward trend continues.
There is no way the sp fall here is simply due to the finance, poor option that it was.
A couple of million finance doesn't account for c70m drop in mcap. The downtrend had actually long before the finance package.
What we have I believe is short activity multiplied by the natural volatility of AIM. The same appears to be happening on AVCT.
There literally are no more pips to squeak now, so hopefully we will see a more rational sp action. I'll be cautious about the retail offer and add a small amount
The SP is a reflection of poor financing nothing more nothing less which is now sorted, all positive RNS’s and forward momentum on both SDC-1801 & SRA737 in the last 12 months have been clouded by RF.
Previously under RF we could have drawn down a further £2.7m + £1.2m Tax credits / totalling £3.9m being enough to fully complete P1a & P1b Inc working capital till Q4 2024.
With the current raise of £2.2m Inc 700k Tax credits and with a deferred portion of salaries that gives us a very comfortable cash runway into 2025 Interestingly we are only £1.7m short on a 24 patient trial in either P1b or P2a Trial - Not a huge shortfall /
IMO SDC-1801 is being packaged up for a partnership / license deal on good P1a results without progressing further and may explain why the switch to naming a P2a trail. As a bonus upcoming news is blinded from the Bod / Markets and brepocitinib P1 data is in the public domain for all to compare.
As always DYOR - Value Play Mk Cap a crazy £7m.